Evidence map›Paper›PMID 31829912›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020

Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial.

Shawn Malone, Soumyajit Roy, Libni Eapen, Choan E, Robert MacRae, Gad Perry, Julie Bowen, Rajiv Samant, Scott Morgan, Julia Craig and 2 more

Erratum issuedAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Estimation of Prostate Cancer Cost in Egypt From a Societal Perspective.Global journal on quality and safety in healthcare · 2023
    Article
  17. Review
  18. Article
  19. Review
  20. Which test for crossing survival curves? A user's guideline.BMC medical research methodology · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Shawn MaloneThe Ottawa Hospital Regional Cancer Center, Ottawa, Ontario, Canada.
Soumyajit RoyThe Ottawa Hospital Regional Cancer Center, Ottawa, Ontario, Canada.
Libni EapenThe Ottawa Hospital Regional Cancer Center, Ottawa, Ontario, Canada.
Choan EThe Ottawa Hospital Regional Cancer Center, Ottawa, Ontario, Canada.
Robert MacRaeThe Ottawa Hospital Regional Cancer Center, Ottawa, Ontario, Canada.
Gad PerryThe Ottawa Hospital Regional Cancer Center, Ottawa, Ontario, Canada.
Julie BowenNortheast Cancer Centre, Sudbury, Ontario, Canada.
Rajiv SamantThe Ottawa Hospital Regional Cancer Center, Ottawa, Ontario, Canada.
Scott MorganThe Ottawa Hospital Regional Cancer Center, Ottawa, Ontario, Canada.
Julia CraigThe Ottawa Hospital Regional Cancer Center, Ottawa, Ontario, Canada.
Kyle MaloneDivision of Radiation Oncology, Department of Radiology, University of Ottawa, Ottawa, Ontario, Canada.
Scott GrimesThe Ottawa Hospital Regional Cancer Center, Ottawa, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDose-escalated radiotherapy (RT) with androgen-deprivation therapy (ADT) is a standard definitive treatment of localized prostate cancer (LPCa). The optimal sequencing of these therapies is unclear. Our phase III trial compared neoadjuvant versus concurrent initiation of ADT in combination with dose-escalated prostate RT (PRT). PATIENTS AND

methodsPatients with newly diagnosed LPCa with Gleason score ≤ 7, clinical stage T1b to T3a, and prostate-specific antigen < 30 ng/mL were randomly allocated to neoadjuvant and concurrent ADT for 6 months starting 4 months before RT (neoadjuvant group) or concurrent and adjuvant ADT for 6 months starting simultaneously with RT (concurrent group). The primary end point was biochemical relapse-free survival (bRFS). Stratified log-rank test was used to compare bRFS and overall survival (OS). Incidence of grade ≥ 3 late RT-related toxicities was compared by log-rank test.

resultsOverall, 432 patients were randomly assigned to the neoadjuvant (n = 215) or concurrent group (n = 217). At 10 years, bRFS rates for the two groups were 80.5% and 87.4%, respectively. Ten-year OS rates were 76.4% and 73.7%, respectively. There was no significant difference in bRFS (

conclusionIn our study, there was no statistically significant difference in bRFS between the two treatment groups. Similarly, no difference was seen in OS or late RT-related toxicities. On the basis of these results, both neoadjuvant and concurrent initiations of short-term ADT with dose-escalated PRT are reasonable standards of care for LPCa.

Indexed as

AgedAged, 80 and overAndrogen AntagonistsAntineoplastic AgentsChemoradiotherapyDisease-Free SurvivalHumansMaleMiddle AgedNeoadjuvant TherapyProstatic NeoplasmsRadiotherapyAndrogen AntagonistsAntineoplastic Agents

Identifiers

PMID31829912
PMCPMC7186584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.